REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating Hunter syndrome, outlining several reasons for the denial.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Why Did RGNX Shares Plummet 19% After-Hours Today?
REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating Hunter syndrome, outlining several reasons for the denial.